Antidote's EU Green Light Brightens Pradaxa Sales Outlook
This article was originally published in Scrip
Executive Summary
The positive opinion granted by the European Medicines Agency to a reversal agent that is expected to be used very rarely brings Boehringer Ingelheim one step closer to a potential healthy injection of additional sales for its anticoagulant Pradaxa (dabigatran). Datamonitor Healthcare predicts that Pradaxa revenues in the EU could rise by 15% by 2020, should the Pradaxa antidote Praxbind (idarucizumab) be approved this year. This is now expected following the positive recommendation from the EMA's Committee for Medicinal Products for Human Use (CHMP).
You may also be interested in...
20 Voices: What Does 2024 Hold For Biopharma?
20 executives in the biopharma industry outline their view of key trends this year. A selection of commentary from a broad industry survey by Scrip.
Scrip Asks…What Does 2024 Hold For Biopharma? Part 6: Therapeutic Area Advances
More than 100 biopharma executives and experts told Scrip their predictions for therapeutic area advances in the coming year. The recent commercial success of GLP-1s in diabetes and obesity and their potential in further disease areas fuelled excitement around the metabolic space. Expectations were also positive in neurology following the launch of Leqembi for Alzheimer’s disease in 2023, while the multiple opportunities to improve cancer treatment kept oncology top of the pile overall.
Scrip Asks…What Does 2024 Hold For Biopharma? Part 5: Clinical Trial Trends
Some 50 experts and executives in the biopharma sector shared their views on the major trends they expect to see driving change in the clinical trials arena in 2024. Artificial intelligence applied to clinical development, greater use of remote monitoring and increased patient diversity in trials were key themes.